Searchable abstracts of presentations at key conferences in endocrinology

ea0044p135 | Neoplasia, cancer and late effects | SFEBES2016

The effect of peptide receptor radionuclide therapy (PRRT) on symptoms and tumour burden in patients with metastatic neuroendocrine tumour (NET)

Abraham Stalin , Casey Ruth , Challis Ben , Pitfield Deborah , Whitley S , Shaw Ashley , Heard Sarah , Saad Zia , Buscombe John , Simpson Helen

Peptide receptor radionuclide therapy (PRRT) is a targeted therapy using synthetic somatostatin analogues attached to a radionuclide, which binds to tumours expressing somatostatin receptors. The aim was to review the role of PRRT in a tertiary referral centre. We retrospectively reviewed a cohort of 25 patients (eight males, 17 females), with a median age of 65, who received Yttrium-90 DOTATATE or Lutetium-177 DOTATATE at Addenbrookes Hospital. The location of the primary tum...

ea0044p151 | Neuroendocrinology and pituitary | SFEBES2016

MicroTSHoma: an emerging clinical entity with ‘atypical’ biochemical features and often ‘normal’ imaging characteristics on MRI

Koulouri Olympia , Moran Carla , Heard Sarah , Lyons Greta , Smith Rob , Aigbirhio Franklin , Antoun Nagui , Cheow Heok , Halsall David , Chatterjee Krish , Gurnell Mark

Background: Heightened awareness, as well as frequent thyroid function testing, have contributed to a recent rise in the incidence of thyrotropinomas. Microadenomas are now increasingly being recognized. The classical textbook description of thyrotropinomas is based on historically reported features in patients who typically had large/invasive lesions. The phenotype of microTSHomas could therefore differ.Methods: We reviewed the records of all TSHomas re...

ea0037gp.20.08 | Pituitary – Hypopituitarism | ECE2015

‘Pseudo-resistance' in macroprolactinomas treated with dopamine agonists; recognising delayed radiological response and a role for 11C-methionine PET-CT in guiding management

Powlson Andrew S , Koulouri Olympia , Steuwe Andrea , Gillett Daniel , Heard Sarah , Hoole Andrew , Scott Miriam , Challis Benjamin G , Antoun Nagui , Cheow Heok K , Mannion Richard J , Gurnell Mark

Background: Endocrine Society guidelines classify macroprolactinomas as ‘resistant’ if there is failure to normalise prolactin, or to achieve radiological tumour shrinkage of >50%, on standard doses of dopamine agonist. In this context, escalation of treatment to maximal tolerable doses and/or referral for surgery is advised. However, we have recently observed several ‘discordant responders’, where tumour shrinkage lags significantly (>6 months) beh...